Thyroid-stimulating immunoglobulin is not associated with aggressive clinicopathologic features in concomitant Graves’ disease and papillary thyroid cancer
- 17 June 2025
- journal article
- research article
- Published by Elsevier in The American Journal of Surgery
- Vol. 247, 116487
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Prognosis of papillary thyroid cancer in patients with Graves’ disease: a propensity score-matched analysisWorld Journal of Surgical Oncology, 2020
- Prevalence and aggressiveness of papillary thyroid carcinoma in surgically-treated graves’ disease patients: A retrospective matched cohort studyJournal of Otolaryngology - Head & Neck Surgery, 2019
- 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of ThyrotoxicosisThyroid®, 2016
- Thyroid Carcinoma in Patients with Graves’ Disease: an Institutional ExperienceEndocrine Pathology, 2014
- Increased Mortality in Patients With Differentiated Thyroid Cancer Associated With Graves' DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2013
- Prevalence of thyroid cancer in Graves’ disease: a retrospective study of a cohort of 103 patients treated surgicallyEuropean Journal of Internal Medicine, 2003
- Multicentre study of thyroid nodules in patients with Graves' diseaseBritish Journal of Surgery, 2000
- Thyroid Nodules in Graves' Disease: Classification, Characterization, and Response to TreatmentThyroid®, 1998
- Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo.Journal of Clinical Investigation, 1995
- The Role of Thyroid-Stimulating Antibodies of Graves' Disease in Differentiated Thyroid CancerNew England Journal of Medicine, 1988